Adrenal insufficiency after megestrol acetate for fertility-sparing treatment of endometrial cancer
•AI is a rare yet potentially life-threatening side effect of MA when used for fertility sparing for EC/AH.•The presentation of AI is highly variable and clinicians should employ a low threshold for investigations.•AI can occur while on MA therapy or after abrupt withdrawal; MA should be tapered upon discontinuation.•Patients on MA may require stress dosing at times of surgery/procedures or acute illness.•Consider progestin IUD as a first line therapy, especially in patients with metabolic comorbidities.
Authors
- Laura Diamond (ORCID: https://orcid.org/0000-0002-6590-4567)
- Eleni V. Dimaraki
- Soyoun Rachel Kim (ORCID: https://orcid.org/0000-0002-5694-5439)
- Lauren Clarfield
- Nashwah Taha
- Sarah E. Ferguson (ORCID: https://orcid.org/0000-0002-2123-3642)
- Shereen Ezzat (ORCID: https://orcid.org/0000-0002-8343-3068)
- Shima Deljoomanesh
Institutions
- University Health Network (CA)
- University of Toronto (CA)
- Scarborough Health Network (CA)
- Women's College Hospital (CA)
- Princess Margaret Cancer Centre (CA)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-09-27
- DOI
- https://doi.org/10.1016/j.gore.2025.101961
- Primary Topic
- Hormonal and reproductive studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00